scholarly article | Q13442814 |
P50 | author | Francis X. Guyette | Q52091909 |
Jason L Sperry | Q114416071 | ||
Timothy Billiar | Q30223707 | ||
Joshua B. Brown | Q44423621 | ||
P2093 | author name string | Andrew B Peitzman | |
Brian S Zuckerbraun | |||
Matthew D Neal | |||
P2860 | cites work | Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma | Q46393514 |
Controlling alcohol problems among hospitalized trauma patients | Q46851570 | ||
Early coagulopathy in trauma patients: an on-scene and hospital admission study. | Q46912713 | ||
Inflammation and the Host Response to Injury, a large-scale collaborative project: Patient-Oriented Research Core--standard operating procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma patient | Q47672528 | ||
In-flight risk of venous thromboembolism and use of tranexamic acid in trauma patients | Q47750682 | ||
Early coagulopathy predicts mortality in trauma | Q47766285 | ||
Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. | Q50491141 | ||
Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration | Q64039987 | ||
Acute traumatic coagulopathy | Q73544166 | ||
Hypothermia for prediction of death in severely injured blunt trauma patients | Q83254056 | ||
Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage | Q84344626 | ||
Prehospital use of tranexamic acid for hemorrhagic shock in primary and secondary air medical evacuation | Q85196373 | ||
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities | Q87104885 | ||
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial | Q28285511 | ||
The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination | Q29617876 | ||
Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? | Q30705540 | ||
Criteria for empiric treatment of hyperfibrinolysis after trauma | Q33402032 | ||
Antifibrinolytic therapy: new data and new concepts | Q33606553 | ||
Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. | Q33810788 | ||
Tranexamic acid in trauma: how should we use it? | Q34345917 | ||
Validation of postinjury multiple organ failure scores | Q35072968 | ||
Disruption of the mucosal barrier during gut ischemia allows entry of digestive enzymes into the intestinal wall | Q35783195 | ||
Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial | Q36465380 | ||
Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations | Q36501096 | ||
Characterization of acute coagulopathy and sexual dimorphism after injury: females and coagulopathy just do not mix. | Q36520866 | ||
Fibrinolysis, inflammation, and regulation of the plasminogen activating system | Q36884356 | ||
Early resuscitation intensity as a surrogate for bleeding severity and early mortality in the PROMMTT study | Q37097012 | ||
The coagulopathy of trauma: a review of mechanisms | Q37292306 | ||
Acute traumatic coagulopathy: from endogenous acute coagulopathy to systemic acquired coagulopathy and back | Q37917494 | ||
Plasmin as a proinflammatory cell activator. | Q38007805 | ||
The acute coagulopathy of trauma: mechanisms and tools for risk stratification | Q38050045 | ||
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities | Q38065891 | ||
An update on the coagulopathy of trauma | Q38160131 | ||
The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial | Q39401875 | ||
Early complementopathy after multiple injuries in humans | Q42578085 | ||
Increased mortality associated with the early coagulopathy of trauma in combat casualties | Q44113097 | ||
Tranexamic acid in the prehospital setting: Israel Defense Forces' initial experience | Q44195932 | ||
Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma | Q44405049 | ||
The incidence and magnitude of fibrinolytic activation in trauma patients | Q44658013 | ||
Stability of tranexamic acid after 12-week storage at temperatures from -20°c to 50°c | Q44839573 | ||
Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. | Q45103688 | ||
Effect of consent rituals on mortality in emergency care research | Q45117645 | ||
The epidemiology of traumatic death. A population-based analysis | Q46056719 | ||
Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? | Q46166562 | ||
Role of the alternative pathway in the early complement activation following major trauma | Q46258966 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | tranexamic acid | Q418666 |
knowledge gap hypothesis | Q1481327 | ||
knowledge gap | Q122958306 | ||
P304 | page(s) | 79-86 | |
P577 | publication date | 2014-07-30 | |
P1433 | published in | Prehospital Emergency Care | Q7239978 |
P1476 | title | Design of the Study of Tranexamic Acid during Air Medical Prehospital Transport (STAAMP) Trial: Addressing the Knowledge Gaps | |
P478 | volume | 19 |
Q89594015 | Accelerating availability of clinically-relevant parameter estimates from Thromboelastogram point-of-care device |
Q33423064 | Acute blood loss during burn and soft tissue excisions: An observational study of blood product resuscitation practices and focused review |
Q34677754 | Advances in the understanding of trauma-induced coagulopathy |
Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
Q26785966 | CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media |
Q47714922 | Development of a Prehospital Tranexamic Acid Administration Protocol |
Q47220418 | Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients |
Q33788878 | Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study |
Q26798015 | Exploring redundant research into the effect of tranexamic acid on surgical bleeding: further analysis of a systematic review of randomised controlled trials |
Q93081627 | Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients |
Q92177202 | Hemorrhagic Shock |
Q49958847 | Intravenous synthetic platelet (SynthoPlate) nanoconstructs reduce bleeding and improve 'golden hour' survival in a porcine model of traumatic arterial hemorrhage |
Q36898573 | Prehospital administration of tranexamic acid in trauma patients |
Q88686949 | Prehospital tranexamic acid: what is the current evidence? |
Q36769313 | Prehospital volume resuscitation--Did evidence defeat the crystalloid dogma? An analysis of the TraumaRegister DGU® 2002-2012. |
Q33457151 | Taking the Blood Bank to the Field: The Design and Rationale of the Prehospital Air Medical Plasma (PAMPer) Trial |
Q37731832 | Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy |
Q90564933 | The effect of tranexamic acid by baseline risk in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients |
Q39364102 | Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage |
Q52841804 | [Tranexamic acid in the German emergency medical service : A national survey]. |
Search more.